Cutera Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cutera stock.
View analyst ratings for Cutera or view top-rated stocks.

Wall Street analysts have given Cutera a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cutera wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cutera is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Cutera.

Cutera, Inc. (NASDAQ:CUTR) released its earnings results on Wednesday, August, 4th. The medical device company reported $0.39 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.49. The medical device company earned $58.59 million during the quarter, compared to the consensus estimate of $50.15 million. Cutera had a net margin of 3.71% and a trailing twelve-month return on equity of 14.36%.
View Cutera's earnings history.

Cutera's stock was trading at $18.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CUTR shares have increased by 164.4% and is now trading at $47.88.
View which stocks have been most impacted by COVID-19.

Cutera updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $215 million-$221 million, compared to the consensus revenue estimate of $205.73 million.

2 analysts have issued 12-month target prices for Cutera's shares. Their forecasts range from $60.00 to $65.00. On average, they expect Cutera's stock price to reach $62.50 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price.
View analysts' price targets for Cutera or view top-rated stocks among Wall Street analysts.

1 employees have rated Cutera CEO David H. Mowry on Glassdoor.com. David H. Mowry has an approval rating of 100% among Cutera's employees. This puts David H. Mowry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Cutera include Outset Medical (OM), BioLife Solutions (BLFS), ViewRay (VRAY), TransMedics Group (TMDX), Natus Medical (NTUS), Semler Scientific (SMLR), AxoGen (AXGN), Zynex (ZYXI), Stereotaxis (STXS), Edap Tms (EDAP), Second Sight Medical Products (EYES), Movano (MOVE), Electromed (ELMD), IRIDEX (IRIX) and FONAR (FONR).
View all of CUTR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cutera investors own include NVIDIA (NVDA), QUALCOMM (QCOM), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), DocuSign (DOCU), Pfizer (PFE), Square (SQ) and Twilio (TWLO).

Cutera trades on the NASDAQ under the ticker symbol "CUTR."

Cutera's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.04%), Gamco Investors INC. ET AL (6.94%), Vanguard Group Inc. (6.24%), First Light Asset Management LLC (5.67%), RTW Investments LP (4.02%) and State Street Corp (3.88%). Company insiders that own Cutera stock include David H Mowry, J Daniel Plants, Joseph E Whitters and Katherine S Zanotti.
View institutional ownership trends for Cutera.

CUTR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, First Light Asset Management LLC, The Manufacturers Life Insurance Company , BlackRock Inc., Essex Investment Management Co. LLC, Russell Investments Group Ltd., Kennedy Capital Management Inc., and Gabelli Funds LLC.
View insider buying and selling activity for Cutera or view top insider-selling stocks.

CUTR stock was purchased by a variety of institutional investors in the last quarter, including RTW Investments LP, Paradigm Capital Management Inc. NY, Bank of Montreal Can, Royal Bank of Canada, Invesco Ltd., Lisanti Capital Growth LLC, Deutsche Bank AG, and Morgan Stanley. Company insiders that have bought Cutera stock in the last two years include David H Mowry, J Daniel Plants, Joseph E Whitters, and Katherine S Zanotti.
View insider buying and selling activity for Cutera or or view top insider-buying stocks.

Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CUTR stock can currently be purchased for approximately $47.88.

Cutera has a market capitalization of $859.06 million and generates $147.68 million in revenue each year. The medical device company earns $-23,880,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

Cutera employs 323 workers across the globe.

Cutera was founded in 1998.

The official website for Cutera is www.cutera.com.

Cutera is headquartered at 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005.

Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at (415) 657-5500 or via email at [email protected]